Northwest Biotherapeutics Inc: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 9, 2022 and accepted by EDGAR at Aug 9, 2022, 16:12 ET.
Management's discussion and analysis
As filed, 18,263 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements included with this report. In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” and similar expressions are used to identify forward-looking statements, but some forward-looking statements are expressed differently. Many factors could affect our actual results, including those factors described under “Risk Factors” in our Form 10-K for the year ended December 31, 2021 and in Part II Item 1A of this report. These factors, among others, could cause results to differ materially from those presently anticipated by us. You should not place undue reliance on these forward-looking statements.
Overview
We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.
Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM ). On May 10, 2022, top line data from the Phase III trial were presented in a scientific conference at the New York Academy of Sciences by one of the investigators in the trial. The presentation was made available publicly on a third party site.
The Company is now working on preparations for seeking regulatory approval of DCVax-L.
Post-COVID difficulties continue to impact supply chains and program operations for the Company as well as for other companies in this industry and others. The independent service firms have limited capacity, and still have some restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time. Other experts have gone on extended leave. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial difficulties and delays.
On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system designed to close and automate the manufacturing of cell therapy products such as DCVax®. The Company acquired 100% of the ownership, and Flaskworks became a wholly-owned subsidiary of the Company. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.
Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company plans to work on preparations for Phase II trials of DCVax-Direct as resources permit.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.
On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative liabilities, accrued expenses and stock-based compensation. We based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.
Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2021. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
Results of Operations
Operating costs:
Operating costs and expenses consist primarily of research and development expenses, including clinical trial expenses, which increase when we are actively participating in clinical trials or we are undertaking substantial one-time expenses following trials, such as for statistical work under the Statistical Analysis Plan, and other activities related to completion and assessment of the trial and its results. The operating costs also include administrative expenses associated with trials, in addition to R&D expenses, and increase as such operating activities grow.
In addition to clinical trial related costs, our operating costs may include ongoing work relating to our DCVax products, including R&D, product characterization, and related matters. Going forward, we are also incurring large amounts of costs to carry out and complete statistical analyses, validation work, data reports and other work associated with analyzing the trial results and proceeding.
Following our acquisition of Flaskworks, our operating costs now include the costs for its ongoing operations and its intellectual property filings.
Our operating costs also include the costs of preparations for the launch of new or expanded clinical trial programs. The preparation costs include payments to regulatory consultants, lawyers, statisticians, sites and others, evaluation of potential investigators, the clinical trial sites and the CROs managing the trials and other service providers, and expenses related to institutional approvals, clinical trial agreements (business contracts with sites), training of medical and other site personnel, trial supplies and other. Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe.
Our operating costs also include legal and accounting costs in operating the Company.
Research and development:
Discovery and preclinical research and development expenses include costs for substantial external scientific personnel, technical and regulatory advisers, and others, costs of laboratory supplies used in our internal research and development projects, travel, regulatory compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical trials.
Because we are a pre-revenue company, we do not allocate research and development costs on a project basis. We adopted this policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number of financial and personnel resources.
General and administrative:
General and administrative expenses include personnel related salary and benefit expenses, cost of facilities, insurance, travel, legal services, property and equipment and amortization of stock options and warrants.
Three Months Ended June 30, 2022 and 2021
We recognized a net loss of $29.7 million and a net income of $4.4 million for the three months ended June 30, 2022 and 2021, respectively.
Research and Development Expense
For the three months ended June 30, 2022 and 2021, research and development expense was $13.6 million and $5.5 million, respectively. The increase was mainly related to SOW 6 that was entered into in April, 2022 for five workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for drafting of key portions of the application and for three required licenses for the
Sawston facility. During the three months ended June 30, 2022, the Company expensed $3.8 million for cash milestones (but only paid $0.5 million) and $5.3 million for stock-based milestones that the Company believes are probable to be achieved and hence to become payable during the contract period. The $5.3 million stock-based compensation expense, for the milestones, were offset by a decrease of $1.9 million of stock-based compensation in research and development which was related to cancellation of certain unvested performance-based awards and less amortization related to previously granted awards.
General and Administrative Expense
General and administrative expenses were $7.9 million and $7.4 million for three months ended June 30, 2022 and 2021, respectively. The increase was mainly related to an increase of approximately $1.7 million in business travel costs, conferences expenses and D&O insurance premiums, and offset by a decrease of $1.2 million stock-based compensation, which were related to the cancellation of certain unvested performance-based awards and less amortization related to previously granted awards.
Change in fair value of derivatives
During the three months ended June 30, 2022 and 2021, we recognized a non-cash loss of $4.3 million and a non-cash gain of $17.5 million, respectively. The 2022 loss was primarily due to the extension of the exercise periods of certain warrants and offset by a decrease of stock price as of June 30, 2022 compared to March 31, 2022. The 2021 gain was primarily due to the decrease of stock price as of June 30, 2021 compared to March 31, 2021.
Loss from Extinguishment of Debt
During the three months ended June 30, 2022 and 2021, we recognized $0.1 million and $0.1 million debt extinguishment loss from the redemption of certain loans, respectively. Changes are consistent compared to the same period of last year.
Interest Expense
During the three months ended and June 30, 2022 and 2021, we recognized interest expense of $1.4 million and $0.8 million, respectively. The increase was primarily due to an increase of outstanding debt as of March 31, 2022 compared to the outstanding balance as of March 31, 2021.
Foreign currency transaction loss
During the three months ended and June 30, 2022 and 2021, we recognized foreign currency transaction loss of $2.8 million and foreign currency transaction gain of $0.3 million, respectively. The loss was due to the strengthening of the U.S. dollar relative to the British pound sterling and Euro. The gain was due to the weakening of the U.S. dollar relative to the British pound sterling.
Six Months Ended June 30, 2022 and 2021
We recognized a net loss of $43.9 million and a net income of $0.3 million for the six months ended June 30, 2022 and 2021, respectively.
Research and Development Expense
For the six months ended June 30, 2022 and 2021, research and development expense was including the expense for milestones under SOW 6 with Advent that are expected to be achieved and become payable in the future) was $18.5 million and $12.4 million, respectively. We incurred an increase in related party research and development expenses of $11.2 million by Advent, of which $9.2 million comprised amounts expensed for SOW 6 milestones that are anticipated to be achieved and become payable in the future (of which the Company only paid $0.5 million during the six months ended June 30, 2022), offset by a decrease of $5.1 million stock-based compensation, which was related to the cancellation of certain unvested performance-based awards and less amortization related to previously granted awards.
We recognized and expensed approximately $14.7 million (including $9.2 million for milestones expected to be achieved and become payable in the future) and $3.5 million in expenses from related parties during the six months ended June 30, 2022 and 2021, respectively.
General and Administrative Expense
General and administrative expenses were $15.8 million and $20.3 million for six months ended June 30, 2022 and 2021, respectively. The decrease was mainly related to a decrease of $7.2 million stock-based compensation, which were related to the cancellation of certain unvested performance-based awards and less amortization related to previously granted awards, and offset by an increase of approximately $2.2 million in business travel costs, conferences expenses and D&O insurance premiums.
Change in fair value of derivatives
During the six months ended June 30, 2022 and 2021, we recognized a non-cash loss of $3.7 million and a non-cash gain of $35.1 million, respectively. The 2022 loss was primarily due to the extension of certain warrants and offset by a decrease of stock price as of June 30, 2022 compared to December 31, 2021. The 2021 gain was primarily due to the decrease of stock price as of June 30, 2021 compared to December 31, 2020.
Gain (Loss) from Extinguishment of Debt
During the six months ended June 30, 2022 and 2021, we recognized debt extinguishment gain of $0.3 million and debt extinguishment loss of $0.1 million, respectively. The gain in 2022 was related to $0.4 million gain from the forgiveness of two PPP loans and offset by a loss of $0.1 million from redemption of certain loans.
Interest Expense
During the six months ended and June 30, 2022 and 2021, we recorded interest expense of $3.3 million and $2.3 million, respectively. The increase was primarily due to an increase of outstanding debt as of December 31, 2021 compared to the outstanding balance as of December 31, 2020.
Foreign currency transaction loss
During the six months ended and June 30, 2022 and 2021, we recognized foreign currency transaction loss of $3.7 million and $0.4 million, respectively. The loss was due to the strengthening of the U.S. dollar relative to the British pound sterling and Euro, and the fluctuation was much higher this year compared to the same period of last year.
Liquidity and Capital Resources
We have experienced recurring losses from operations since inception. We have not yet established an ongoing source of revenues and must cover our operating expenses through debt and equity financings to allow us to continue as a going concern. Our ability to continue as a going concern depends on the ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.
We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern within one year after the condensed consolidated financial statements were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.
Cash Flow
Operating Activities
During the six months ended June 30, 2022 and 2021, net cash used in operations were approximately $27.8 million and $20.0 million, respectively. The increase in cash used in operating activities was primarily attributable to an increase in clinical trial related expenditures.
Financing Activities
We received approximately $9.5 million cash from issuance of 13.1 million shares of common stock during the six months ended June 30, 2022.
We received approximately $9.6 million and $4.1 million, in cash from the exercise of warrants and options during the six months ended June 30, 2022 and 2021, respectively.
We received approximately $0.6 million from issuance of multiple loans to individual lenders during the six months ended June 30, 2022. We received approximately $10.0 million cash proceeds from a loan from a commercial lender, $1.9 million cash from loans from various third-party lenders and $0.4 million from PPP loans during six months ended June 30, 2021.
We made aggregate debt payments of $5.3 million and $0.8 million during the six months ended June 30, 2022 and 2021, respectively.
Other factors affecting our ongoing funding requirements include the number of staff we employ, the number of sites, number of patients and amount of activity in our clinical trial programs, the costs of further product and process development work relating to our DCVax products, the costs of preparations for Phase II trials, the costs of expansion of manufacturing, and unanticipated developments. The extent of resources available to us will determine which programs can move forward and at what pace.
Off-Balance Sheet Arrangements
Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Market risk
As filed, 2,778 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Market risk represents the risk of loss that may result from the change in value of financial instruments due to fluctuations in its market price. Market risk is inherent in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market participants refrain from transacting in normal quantities and/or at normal bid-offer spreads. Our exposure to market risk is directly related to derivatives, debt and equity linked instruments related to our financing activities.
Our assets and liabilities are overwhelmingly denominated in U.S. dollars. We do not use foreign currency contracts or other derivative instruments to manage changes in currency rates. We do not now, nor do we plan to, use derivative financial instruments for speculative or trading purposes. However, these circumstances might change.
The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.
The sensitivity analyses of the interest rate sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take to mitigate the impact of any adverse changes in the key estimates.
Based on our analysis, as of June 30, 2022, the effect of a 100+/- basis point change in interest rates on the value of our financial instruments and the resultant effect on our net loss are considered immaterial.
Controls and procedures
As filed, 1,237 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation as of June 30, 2022, of the design and operation of our disclosure controls and procedures, as such terms are defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, management concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $477.0k | us-gaap:Revenues |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $880.0k | us-gaap:Revenues |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $13.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $18.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$21.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$33.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $1.4m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $3.3m | us-gaap:InterestExpense |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$29.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$43.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 1,003,976 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 981,737 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$27.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-06-30 | $4.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $7.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $27.5m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $98.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $119.2m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $26.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-06-30 | −$91.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-22-002177. Last ingested by Listed: Nov 14, 2026, 21:35 ET. Listed shows no prices and gives no investment advice.